Print this page    •   Back to Web version of article

Nevirapine Recommended for Approval in Combination With Nucleosides

Read Mark Mascolini's full report in the July, 1996 Journal of the International Association of Physicians in AIDS Care
The FDA's Antiviral Drugs Advisory Committee recommended that nevirapine--the first nonnucleoside reverse transcriptase inhibitor considered for licensing--should be approved for use with one or, if possible, two nucleoside analogs that a person has not taken before. The panel chose not to specify a disease stage to which use of the drug should be restricted. These are the key findings so far: And there were a few surprises:

This article was provided by the International Association of Physicians in AIDS Care


©1996, Medical Publications Corporation




This article was provided by International Association of Physicians in AIDS Care. It is a part of the publication Journal of the International Association of Physicians in AIDS Care. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art12195.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.